Related Experiment Video

Updated: Aug 17, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells

M Amit-Vazina1, S Shishodia, D Harris

  • 1Department of Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

British Journal of Cancer
|June 23, 2005
PubMed

Insights

Atiprimod effectively inhibits multiple myeloma cell proliferation and induces apoptosis by blocking key survival pathways. This drug shows promise for future multiple myeloma therapies, targeting resistant cancer cells.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma (MM) is a fatal blood cancer with high recurrence and treatment resistance.
  • Existing treatments for MM are aggressive, yet nearly all patients experience relapse.
  • Atiprimod, previously studied for anti-inflammatory effects and bone resorption inhibition, is a potential therapeutic candidate.

Purpose of the Study:

  • To investigate the anti-myeloma activity of Atiprimod.
  • To elucidate the mechanism of action of Atiprimod in multiple myeloma cells.

Main Methods:

  • Assessing Atiprimod's effect on myeloma cell line proliferation (U266-B1, OCI-MY5, MM-1, MM-1R).
  • Analyzing cell cycle progression, STAT3 activation, and apoptosis markers (Bcl-2, Bcl-X(L), Mcl-1, caspase 3, PARP).
  • Evaluating Atiprimod's impact on primary patient-derived myeloma cells.

Main Results:

  • Atiprimod significantly inhibited proliferation in all tested myeloma cell lines in a dose- and time-dependent manner.
  • Atiprimod induced G(0)/G(1) cell cycle arrest and apoptosis by downregulating antiapoptotic proteins and activating caspase 3.
  • The drug suppressed proliferation of primary myeloma colony-forming cells from newly diagnosed patients.

Conclusions:

  • Atiprimod demonstrates potent anti-myeloma activity through cell cycle arrest and apoptosis induction.
  • Inhibition of the IL-6/STAT3 pathway and downregulation of antiapoptotic proteins are key mechanisms.
  • Atiprimod shows potential as a novel therapeutic agent for multiple myeloma, including resistant forms.

More Related Videos

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death09:18

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death

Published on: December 27, 2016

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...